A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma

BACKGROUND: Bevacizumab has promising activity against recurrent glioblastoma (GBM). However, acquired resistance to this agent results in tumor recurrence. We hypothesized that vorinostat, a histone deacetylase (HDAC) inhibitor with anti-angiogenic effects, would prevent acquired resistance to beva...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Puduvalli, Vinay K, Wu, Jing, Yuan, Ying, Armstrong, Terri S, Vera, Elizabeth, Wu, Jimin, Xu, Jihong, Giglio, Pierre, Colman, Howard, Walbert, Tobias, Raizer, Jeffrey, Groves, Morris D, Tran, David, Iwamoto, Fabio, Avgeropoulos, Nicholas, Paleologos, Nina, Fink, Karen, Peereboom, David, Chamberlain, Marc, Merrell, Ryan, Penas Prado, Marta, Yung, W K Alfred, Gilbert, Mark R
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7686463/
https://ncbi.nlm.nih.gov/pubmed/32166308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa062
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados